Amifampridine

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 451 publications

HSR26-256: Real-World Evidence of Predictors of Time to Amifampridine Discontinuation and Survival in Patients With Cancer-Associated and Non-Cancer-Associated Lambert-Eaton Myasthenic Syndrome in the United States.

HSR26-256: Real-World Evidence of Predictors of Time to Amifampridine Discontinuation and Survival in Patients With Cancer-Associated and Non-Cancer-Associated Lambert-Eaton Myasthenic Syndrome in the United States.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 16, 2026

Efficacy and Safety of Amifampridine in Myasthenia Gravis: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial.

Efficacy and Safety of Amifampridine in Myasthenia Gravis: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial.

Journal: Neurology

Published: April 07, 2026

HSR26-256: Real-World Evidence of Predictors of Time to Amifampridine Discontinuation and Survival in Patients With Cancer-Associated and Non-Cancer-Associated Lambert-Eaton Myasthenic Syndrome in the United States.

HSR26-256: Real-World Evidence of Predictors of Time to Amifampridine Discontinuation and Survival in Patients With Cancer-Associated and Non-Cancer-Associated Lambert-Eaton Myasthenic Syndrome in the United States.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 30, 2026

Clinical characteristics, cerebellar MR spectroscopy and response to 3,4-diaminopyridine in spinocerebellar ataxia 27B: the Sheffield Ataxia Centre experience.

Clinical characteristics, cerebellar MR spectroscopy and response to 3,4-diaminopyridine in spinocerebellar ataxia 27B: the Sheffield Ataxia Centre experience.

Journal: Journal of neurology

Published: August 11, 2025

PharmVar GeneFocus: NAT2-Genetic Variation and Updated Nomenclature.

PharmVar GeneFocus: NAT2-Genetic Variation and Updated Nomenclature.

Journal: Clinical pharmacology and therapeutics

Published: July 30, 2025

Lambert Eaton Myasthenic Syndrome.

Lambert Eaton Myasthenic Syndrome.

Journal: International review of neurobiology

Published: July 17, 2025

Epidemiological analysis of Lambert-Eaton myasthenic syndrome in Türkiye: insights from a nationwide electronic health database.

Epidemiological analysis of Lambert-Eaton myasthenic syndrome in Türkiye: insights from a nationwide electronic health database.

Journal: Frontiers in neurology

Published: July 16, 2025

The recognition, physiology, and treatment of Lambert-Eaton myasthenic syndrome.

The recognition, physiology, and treatment of Lambert-Eaton myasthenic syndrome.

Journal: Disease-a-month : DM

Published: June 21, 2025

Long-term Efficacy and Safety of Amifampridine Phosphate (Firdapse®) in Japanese Patients with Lambert-Eaton Myasthenic Syndrome (LMS-005 Study).

Long-term Efficacy and Safety of Amifampridine Phosphate (Firdapse®) in Japanese Patients with Lambert-Eaton Myasthenic Syndrome (LMS-005 Study).

Journal: Internal medicine (Tokyo, Japan)

Published: June 18, 2025

The impact of experimental variables in twitch tension recording on triphasic action of phospholipase A2 neurotoxins at the neuromuscular junction and acetylcholine release.

The impact of experimental variables in twitch tension recording on triphasic action of phospholipase A2 neurotoxins at the neuromuscular junction and acetylcholine release.

Journal: Toxicon : official journal of the International Society on Toxinology

Published: June 05, 2025

Combined treatment with antitoxin and 3,4-diaminopyridine improves survival outcomes after lethal botulinum neurotoxin challenge.

Combined treatment with antitoxin and 3,4-diaminopyridine improves survival outcomes after lethal botulinum neurotoxin challenge.

Journal: Molecular medicine (Cambridge, Mass.)

Published: May 04, 2025

Congenital Myasthenic Syndrome With Adult Onset Due to the Novel Heterozygous c.1399_1404del Variant in the Downstream of Tyrosine Kinase-7 (DOK7): A Case Report.

Congenital Myasthenic Syndrome With Adult Onset Due to the Novel Heterozygous c.1399_1404del Variant in the Downstream of Tyrosine Kinase-7 (DOK7): A Case Report.

Journal: Cureus

Published: April 03, 2025

Showing 1-12 of 451

Last Updated: 06/30/2026